Country: Australia
Bahasa: Inggeris
Sumber: Department of Health (Therapeutic Goods Administration)
furosemide, Quantity: 40 mg
Ipca Pharma (Australia) Pty Ltd
Tablet
Excipient Ingredients: sodium starch glycollate type A; maize starch; lactose monohydrate; magnesium stearate; pregelatinised maize starch
Oral
100, 250, 1000
(S4) Prescription Only Medicine
Oedema Frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,Parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral frusemide as soon as practical.,Hypertension Oral Frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.
Visual Identification: White to off-white, round tablets, embossed 'F4' on one side and breakline on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered